STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Selank analogs / TP-7 variants

Also known as

TP-7 · TP7 variants · Selank family · Selank (TP-7) · Selanc · Селанк · Thr-Lys-Pro-Arg-Pro-Gly-Pro family · TKPRPGP family · N-Acetyl Selank · N-Acetyl Selank Amidate · NA-Selank / NA-Selank Amidate · Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (dual-capped form) · tuftsin + Pro-Gly-Pro heptapeptide family

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Niche talk Systemic Nasal Cognitive / nootropic peptides

Systemic CNS family — nasal delivery dominates for whole-brain anxiolytic/nootropic talk, not local tissue repair.

What people say This family separates parent Selank from N-acetyl and dual-capped amidate forms. Parent has limited Russian human literature; capped variants largely inherit claims by analogy. Doses people talk about
Plain-Selank community daily total~250–900 mcg/day nasal, usually split 1–3 times

The densest preserved Western discussion band; unverified products and varying spray delivery limit comparisons.

N-acetyl individual reports200 mcg nasal once or twice daily; separate 400–550 mcg single administrations

One author reported little at 200 mcg once/twice or 400–550 mcg once, with uncertain eye strain or twitching; another described 2–3 hours of anxiety after one 200 mcg administration.

Parent clinical-secondary course amount~250–300 mcg per nasal administration, 2–3 times daily

Secondary Russian summaries use this multi-week cadence and sometimes cite totals up to ~2,700 mcg/day; no primary Western protocol or capped-form equivalence was established here.

Rows are separate clinical-secondary, community and individual-report contexts, not a progression. SubQ and high protocol-chart material remain in the full notes.

Half-life & effect duration

Half-life in the body
  • Parent Selank · lab breakdownAbout 2 minutes
  • Capped variants · vendor estimateAbout 10–20 minutes
Felt duration people report
  • Parent · community duration estimateAbout 3–6 hours of calm
  • Capped variants · marketed effect windowAbout 4–6 hours
  • After-course reportsFading within 1–2 days, several days of residual calm, or over a week in older reports
  • Other accountsNo effect, 2–3 hours of anxiety, or multi-day sleep disruption
Timing context & sources
How it may feel Reports range from subtle calm to no effect, flattening or paradoxical anxiety and insomnia. Two negative nasal accounts involved N-acetyl or uncertain products and important sleep, Semax, cannabis or medication confounds.
Cycles people discuss Parent-product summaries emphasize roughly 10–14-day nasal courses; community and vendor calendars extend to 14–30 days or pulse use. None establishes one schedule for all three molecular forms. Timing Community nasal routines are usually morning/daytime, once daily or split 2–3 times daily; afternoon wear-off is a reported reason for a later dose. Parent Selank clinical schedules and capped-variant spray charts are not interchangeable. These reports do not validate a dosing interval. Stacks Semax plus Selank is the dominant calm-focus pairing, in parent or capped forms. Timing, amounts and ratios vary; benzodiazepine and other calming combinations have sparse interaction data and are not self-stacking guidance. Watch for Source / identity risk: Mislabel (plain vs N-acetyl vs dual-capped), underfilled vials, wrong spray concentration, bacterial contamination of multi-use bottles, peptide degradation.
Related
SelankSemaxNoopeptDihexaPinealon

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A human intranasal parent half-life is not established for Selank or its capped variants.

The familiar ~2-minute number describes rapid degradation in an in-vitro setting. Rat distribution and gene-expression experiments support biological activity after exposure but do not produce a human nasal terminal half-life.

No replicated human plasma curve was located; secondary Russian summaries are thin on assay, route and analyte details, and capped variants lack independent human PK.

Felt duration people report

Onset and felt duration vary from null or subtle calm to short adverse reactions or multi-day sleep disruption.

One N-acetyl account described 2–3 hours of increased anxiety after 200 mcg nasal. Another intranasal account described no calm across about 200–600 mcg/day and worsening sleep, later disclosing pre-existing symptoms and additional sleep medicines.

Different or uncertain forms, unverified sprays, co-exposures, baseline symptoms and self-selection; a controlled parent-Selank comparison reported effects after a course, not per-dose felt duration.

  • Paradoxical insomnia/anxiety reaction to Selank? (opens in a new tab)OP and visible same-author follow-ups reviewed: intranasal use estimated at 200 mcg per spray, then about 400 mcg/day and briefly 600 mcg/day; no calm, worse sleep/anxiety, gradual normalization after stopping; later disclosed agomelatine 25 mg and diphenhydramine plus prior sleep/anxiety history.Unverified product and spray estimate, home preparation not reproduced, baseline symptoms and later medicines confound causality; no controlled rechallenge.
  • Selank causing or amplifying anxiety? (opens in a new tab)OP and correction reply reviewed: one approximately 200 mcg N-acetyl Selank nasal administration, with reported anxiety for 2–3 hours; regular Semax use and cannabis context disclosed.Single unverified exposure, co-exposure and driving/anxiety context; no blinded comparison or confirmation of product identity.
  • NA-Selank experiences and odd effects from higher dosages (opens in a new tab)OP plus distinct commenter reviewed: OP reported ~200 mcg once/twice daily and ~400 or ~550 mcg once with little effect and uncertain eye strain/twitching; another author described an accidental 750 mcg exposure with 15–20 minutes of intense distant/weak feeling.Two different authors must remain separate; unverified N-acetyl products, uncertain adverse attribution and no same-author outcome update.
  • Selank versus phenazepam in anxiety disorders (opens in a new tab)PubMed abstract reviewed: comparative 60-patient parent-Selank study, anxiolytic findings and reported persistence for one week after the last dose.Abstract omits exact dose, route and detailed methods; small Russian comparative study, not capped-variant evidence or per-dose PK.

What people say 14

  • Anxiolytic (primary family hook): Lower generalized anxiety, rumination, and baseline edge without heavy benzo-style sedation or memory fog — core claim across plain and capped forms. forum
  • Focus under stress: Easier task focus when anxiety is less distracting; pure nootropic credit weaker than Semax-class and hard to split from anxiolysis/placebo. forum
  • Mood smoothing: Steadier multi-day emotional reactivity and stress handling more than a single-dose buzz or euphoria. forum
  • Variant duration claims: Stabilized (N-acetyl / amidate) forms credited with longer subjective feel per dose or fewer daily administrations — community PK bet, not published NA-Amidate human half-life tables. forum
  • vs Semax typology: Community shorthand — Selank family = calm / anxiolytic; Semax family = activating / focus. Useful stacking language, not a Western head-to-head RCT. forum
  • Stack halo warning: Semax+Selank, caffeine, racetams, sleep changes, and load management often co-occur — single-agent credit is unreliable. forum
  • Calm energy / antiasthenic narrative: Russian clinical summaries of parent Selank report antiasthenic and mild psychostimulant properties alongside anxiolysis (not “knocked out”). Zozulia et al. 2008 (PMID 18454096) vs medazepam in GAD/neurasthenia (n≈62) is the most-cited human comparison. trial
  • vs Medazepam (parent): Comparable anxiolytic scale changes in the 2008 GAD/neurasthenia trial with additional antiasthenic/psychostimulant benefits the benzo arm lacked; leu-enkephalin increases correlated with improvement in the Selank group. trial
  • vs Phenazepam (parent): Secondary clinical comparisons describe comparable anxiolytic efficacy without sedation, muscle relaxation, tolerance development, or withdrawal syndrome characteristic of phenazepam (e.g. Medvedev et al. PMID 25176261). trial
  • Non-sedating / non-dependence narrative: Russian clinical summaries repeatedly claim anxiolysis without amnesia, classic benzo withdrawal, or dependence package — this is the marketing and forum refrain; long-term gray-market self-use safety is not proven by that claim. trial
  • BDNF / learning hooks (preclinical, parent): Animal work links intranasal Selank to hippocampal BDNF expression and learning/memory endpoints; forums recycle as study/stress-performance support. animal
  • Immune thread (secondary): Parent literature notes cytokine/chemokine gene shifts, IFN-alpha induction talk, phagocytic/tuftsin heritage; less central in Western anxiety-first threads. trial
  • vs benzos (user language): “Takes the edge off without destroying drive or next-day fog” — anecdotal comparison only; not medical equivalence. anecdote
  • Enkephalin / endogenous peptide angle: Parent lab work shows inhibition of enkephalin-degrading enzymes and leu-enkephalin support in clinical/lab framing — used online to explain calm without opioid sedation. Assumed (not proven) for capped analogs. trial

Doses people talk about 14

  • Community nasal daily total (plain Selank, densest Western band): ~250–900 mcg/day total, usually split 1–3×. forum
  • Lower plain-Selank discussion band: ~200–300 mcg/day, sometimes as one administration. Posters describe this as a response-checking amount; that behavior is not a validated starting step. forum
  • Common working band (plain): ~250–500 mcg per administration, 1–2× daily; or ~300 mcg × 2–3× daily when mirroring Russian multi-dose cadence. forum
  • Higher community / protocol-chart band (plain): Toward ~600–1,200+ mcg/day split; anecdotal logs mention ~500–600 mcg nasal daily for months in open self-reports and occasional ~1 mg/day short runs — still not trial-proven ladders. forum
  • N-Acetyl Selank / NA-Selank Amidate nasal charts (vendor/forum): Research sprays are marketed at ~100–300 mcg per pump, commonly ~300 mcg/actuation in sample protocols. Sample charts describe one pump 2–3× daily, or ~600–900 mcg/day total, and historical forum talk calls ~300 mcg usual while noting smaller amounts. These commerce and forum descriptions are not a validated titration ladder. forum
  • Capped-form lower-band talk: Some secondary/vendor writeups claim dual-capped forms are “higher potency per mg” or estimate longer effective windows → reduce toward ~150–300 mcg/day as a starting discussion band. Practice often still sits in the same hundreds-of-mcg band as plain; this is not formal PK proof. forum
  • Split dosing rationale: Short plasma half-life of parent → multi-times-daily nasal, not weekly depot. Even capped forms stay 1–3× daily in practice. forum
  • Timing: Morning/daytime common; evening less consistently flagged for insomnia than Semax-class, but flatness or next-day dullness appears in minority logs. forum
  • As-needed vs scheduled: High-stress days only vs daily through a fixed ~10–21 day course then stop — both patterns common. Single morning-only dosing sometimes leaves afternoon gaps if all-day coverage is the goal. forum
  • Uncertainty / quality: Fill errors, underdosed sprays, wrong analog (plain vs acetyl-only vs acetyl-amidate), and dead volume make labeled mcg ≠ delivered mcg. forum
  • SubQ (minority; not labeled clinical route for any form): Starting talk often ~150–250 mcg/day SC; common “standard” forum band ~200–500 mcg/day SC once daily; some injectable charts list ~150 mcg start → ~200–250 mcg “sweet spot” → ~300 mcg upper. Occasional commercial charts list ~0.5 mg injectable — high vs many forum SC logs; treat as vendor noise unless tied to a specific study. NA-Amidate-specific SubQ charts thinner than plain. forum
  • Framing: Community and secondary-source research-discussion ranges only — not medical advice, not prescriptions, not validated Western protocols. Gray-market mcg labels are not pharmacy-grade identity. Do not copy one form’s chart onto another 1:1. forum
  • Nasal vs SubQ dose relationship (bro lore): Injection often discussed at lower mcg than nasal on assumed bioavailability grounds; nasal still preferred for “CNS / nose-to-brain” framing and for matching the studied parent route. Circulating bioavailability % figures on vendor blogs are usually not primary PK citations. Community debate: nasal = faster acute; SubQ = more “stable” all-day feel for some logs. forum
  • Russian / clinical secondary bands (parent): Multi-week courses in secondary summaries often cite ~250–300 mcg per administration × 2–3× daily; research-protocol language at Russian institutes has been summarized with upper figures up to ~2,700 mcg/day for ~21 days — not a Western standard and not automatically transferable to capped analogs. trial

How it may feel 8

  • Minutes–hours 1–3 (acute nasal): Subjective onset often ~15–60 minutes (sometimes tens of minutes to a few hours); subtle calm, reduced social edge, quieter mental noise, or nothing day one. Not a recreational high. forum
  • Same-day duration talk: Per-dose coverage often framed ~3–6 hours for some → multi-dose daily schedules; others describe a quieter multi-day baseline more than discrete “kicks.” Capped forms marketed as longer; practice still often 1–3× daily. forum
  • Day 1: Subtle calm same day for responders; many first doses feel null. Nasal irritation or post-nasal drip can show before mood claims. forum
  • Days 1–3: Reports include subtle or null effects, headache, drip and first-dose oddities, but also paradoxical anxiety or stimulation. One 200 mcg N-acetyl nasal report described increased anxiety for 2–3 hours; regular Semax and cannabis context limit attribution. forum
  • Days 3–7: Accounts diverge: some describe reduced anticipatory worry, while others remain null or report worse anxiety and sleep. One intranasal account moved from about 200 to 400 mcg/day and briefly 600 mcg/day without calm; pre-existing sleep/anxiety and later sleep medicines confounded the timeline. forum
  • Weeks 2–4 / extended community courses: Some continue toward ~14–21 days or ~2–4 weeks; plateau, flatness, “already got what I needed,” or schedule end are common stops. Non-responders remain common. forum
  • Weeks 1–2 (Russian-style course window): Mid-course reassessment for cumulative stress resilience; 10–14 day blocks mirror labeled Russian parent-product course length. Reassess nasal irritation and sleep. trial
  • After course ends: Limited rebound vs benzos in clinical/community framing; residual calm can linger days for some; others fade within 1–2 days. Phenazepam-comparison secondary notes mention anxiolytic effects persisting ~1+ week after last dose in parent work. trial

Cycles people discuss 11

  • Community extension: ~14–21 days frequently; some protocol blogs extend to ~2–4 weeks or cite ~30-day / “one month on, one month off” frameworks — longer courses have thinner formal study support. forum
  • Vendor/sample NA-Amidate language: Up to ~14 days on, then minimum ~1 week off before another two-week-style course if repeating — appears in research-chem guide sample protocols. forum
  • On/off symmetry talk: “Match time-off roughly to time-on” (e.g. 2–4 weeks on, 2–4 weeks off) appears as convenience pattern, not a hard PK rule. forum
  • As-needed pulse: Acute high-anxiety or performance days without a full multi-week course — reported after someone knows their response. anecdote
  • 5-on / 2-off micro-cycles: Occasional workplace-style logs (weekdays on, weekends off) at fixed daily mcg — not clinical design. anecdote
  • With Semax family: Usually same calendar block (both on together for “calm focus”), not staggered multi-week cycles. Some protocols suggest starting Selank-class alone ~5–7 days before adding Semax-class to attribute sides. forum
  • Re-runs: Before travel, exams, launches, or seasonal high-demand work more than open-ended multi-month continuous use. forum
  • Form-switching: Restart or switch plain / N-acetyl / dual-capped between cycles — no controlled comparisons of which form “wins.” forum
  • Tolerance talk: No classic benzo-withdrawal package in community/Russian summaries; whether subtle blunting develops with long continuous use is unsettled and sparsely logged. Short courses remain the conservative discussion norm. forum
  • Classic Russian-style parent course: ~10–14 days nasal, matching labeled product course language and common clinical summary length. trial
  • Rest between Russian-style courses: Secondary product language often mentions ~1-month breaks or ~1–3 weeks between re-courses depending on source; applied to Western research-chem by analogy. trial

Timing 12

  • Subjective onset: Often ~15–60 minutes nasal for responders (anecdote; not controlled human PK for every form). SubQ onset often described slightly slower (~15–30 minutes). forum
  • Subjective per-dose window (parent): Roughly a few hours (~3–6 h talk common in secondary/community writeups) of noticeable calm coverage for some → 2–3× daily; others describe quieter baseline building over days of a course. forum
  • Stabilized variant claims: Dual capping (N-acetyl + C-amide) hypothesized to slow proteolytic degradation; vendor/secondary estimates range widely (e.g. “10–20 minutes plasma” vs “4–6 hour effective window” marketing) — not independent published human PK for N-Acetyl Selank Amidate. Treat as structure analogy + commerce lore. forum
  • Still split dosing in practice: Even with “longer lasting” marketing, community logs and sample charts stay 1–3× daily nasal — not weekly depot-style. forum
  • Split dosing rationale: Afternoon wear-off after morning-only dosing is a common reason for AM/PM or 2–3× schedules. forum
  • Nasal technique matters more than half-life tables: Congestion, sniff force, head tilt, and posterior drip shape delivered dose and feel. forum
  • Do not 1:1 copy charts: Plain Selank clinical mcg totals and NA-Selank Amidate vendor pumps are different product cultures. forum
  • Parent degradation versus human PK: The often-cited ~2-minute figure is an in-vitro degradation observation, not an established human intranasal parent half-life. Rat tracer/distribution work and secondary claims of rapid plasma decline do not supply a replicated human terminal PK curve; community multi-dose schedules cannot fill that gap. trial
  • Parent nasal absorption notes: Russian product/secondary summaries describe rapid nasal absorption, plasma detection within ~30 seconds, brain tissue within ~2 minutes in animal PK, high nasal bioavailability figures in secondary sources (~90% class claims circulate), and progressive plasma decline over minutes. trial
  • Course vs acute: Acute situational calm vs multi-day “stress resilience” after repeated administrations — both claimed; course framing is closer to how Russian Selank products are labeled. forum
  • Why nasal not oral: Oral peptide framed as unstable / poor CNS delivery; intranasal is the registered and preferred research route for CNS goals. trial
  • Why effects last longer than PK: Downstream signaling (GABA gene-expression shifts in animal work — e.g. Volkova et al. PMC4757669; enkephalin pathways; BDNF changes) is used to explain hours-to-days functional effects after brief exposure. Cascade/regulatory-peptide framing (Ashmarin line) says single peptide exposure can start multi-day regulatory waves. animal

More on what it is 9

  • Main named forms: (1) Plain Selank / TP-7 / Selanc 0.15% (Russian pharmacy nasal product culture); (2) N-Acetyl Selank (N-terminus only); (3) N-Acetyl Selank Amidate (Ac-TKPRPGP-NH2 — dual-capped, most common Western research-chem “stable Selank”). forum
  • Why variants exist: Acetyl and/or C-amide end-caps marketed to slow exopeptidase attack, stretch subjective duration, and/or raise potency-per-mcg vs plain. Structure-analogy claims, not head-to-head published human PK for every cap combination. forum
  • Why people search the family: Russian anxiolytic/nootropic pedigree + “benzo-adjacent calm without classic sedation/dependence package” hook; almost always discussed next to Semax family. forum
  • Name traps: Plain Selank ≠ N-Acetyl Selank ≠ N-Acetyl Selank Amidate. Vendors blur names; “Selank” on a Western spray may mean any of the three. Russian pharmacy Selank ≠ research-chem analog by default. forum
  • What the family is: Synthetic heptapeptide backbone Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP / TP-7): tuftsin fragment (Thr-Lys-Pro-Arg) extended with C-terminal Pro-Gly-Pro for metabolic stability vs native tuftsin. Developed at Institute of Molecular Genetics, Russian Academy of Sciences (with Zakusov Institute pharmacology work). Molecular weight of parent ~751.9 Da. trial
  • Mechanism talk (compressed online): GABA-A allosteric modulation narrative (benzo-like spectrum without classic benzo side package in Russian summaries), enkephalinase inhibition / leu-enkephalin support, monoamine/serotonin metabolism shifts, hippocampal BDNF elevation (rodent), secondary immune/cytokine (IL-6, IFN, T-helper balance) from tuftsin lineage. Forums: “GABA + stress peptides + BDNF.” trial
  • Evidence honesty: Parent Selank has denser Russian clinical data (GAD/neurasthenia vs medazepam and phenazepam comparisons) and a registered 0.15% nasal product; English-indexed Western RCTs sparse. N-Acetyl and dual-capped amidate human trials essentially absent — most “effects” language is extrapolated from parent. trial
  • Not: Not a benzodiazepine, not FDA/EMA-approved, not one interchangeable molecule across labels, not dose-identical across plain vs capped forms, not the same as Semax. trial
  • Lens: Vendor dose charts, “Xanax without fog,” SubQ protocols, and blend ratios are discussion/commerce data — research-only framing, not prescriptions. forum

Stacks 16

  • Semax + Selank (dominant pair): Classic Russian “calm focus” stack — Semax-class for activating attention, Selank-class for anxiolysis. Often same course length and both nasal. Ratio talk is usually independent full doses of each in their own common bands, not a fixed mg:mg pre-blend. forum
  • Stabilized dual pair: N-Acetyl Selank Amidate + N-Acetyl Semax Amidate (NASA) — same typology with modified analogs when users want longer perceived duration or different spray stock. forum
  • Example community stack bands (discussion ranges only): Semax-class ~100–600 mcg nasal (often morning); Selank-class ~250–500 mcg nasal (morning, midday, or later). Sample protocol pages cite e.g. Semax 100–200 mcg + Selank 250 mcg AM together, or Semax 200–300 mcg AM + Selank 250–500 mcg evening split. SubQ stack charts sometimes list Semax ~500–800 mcg + Selank ~400–500 mcg maintenance — commerce protocol language, not RCTs. forum
  • Selank-first protocol-blog pattern: Some blogs describe 5–7 days of Selank-class alone before adding Semax-class to make attribution easier. This is a reported sequencing convention, not a validated instruction. forum
  • Timing within the pair: Common talk is Semax-class morning/earlier day and Selank-class later (or both multi-dose); others dose together. Not standardized. forum
  • Noopept + Selank-class: Older nootropic-forum memory/focus + anxiety-control pairing. forum
  • Caffeine / L-theanine layer: Common lifestyle stack; watch overstimulation if Semax-class is also present. forum
  • Racetams / other nootropics: Piracetam, phenylpiracetam, etc. in legacy stacks — confounds attribution. forum
  • Magnesium / sleep hygiene / adaptogens: Lifestyle co-stack (Mg L-threonate, ashwagandha, rhodiola) discussed as complementary calm tools without formal interaction data. forum
  • DSIP / sleep agents: Sometimes discussed when anxiety and sleep interact; separate goals from daytime calm. Pre-mixed clinic/commerce blends (e.g. Semax+Selank+DSIP) appear — ratios vary by vendor. forum
  • Dihexa / P21 / PE-22-28 / other cognitive peptides: Mentioned in aggressive nootropic stacks; sparse controlled data and hard to isolate effects. forum
  • Stimulant meds (e.g. ADHD Rx): Harm-reduction threads ask about stacking Selank-class with prescribed stimulants; no solid interaction tables. forum
  • Avoid double-calm stacking blindly: Multiple anxiolytics + high Selank-class → flat / unmotivated / cognitive dulling reports in anecdotes. anecdote
  • Solo-use discussion: Some posters describe trying a Selank-class agent alone for a few days before combining products so later effects are less confounded; this is a reporting pattern, not a recommendation. forum
  • Diazepam combination (parent preclinical): Animal work (Kasian et al. 2017, PMID 28280289) found Selank + diazepam combination most effective under chronic stress conditions; clinical Russian work has also explored Selank with benzodiazepine tranquilizers for optimization (e.g. PMID 26356395). Not a human self-stacking guide — flags complementary pharmacology, not “safe to combine without supervision.” trial
  • Not a benzo swap: Non-sedating vs benzos framing is discussion language — do not change prescribed meds unsupervised. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 19

  • Nasal irritation (most common): Burning, stinging, dryness, sneezing, runny nose, post-nasal drip / throat taste when solution runs posteriorly — technique- and concentration-dependent. forum
  • Headache / sinus pressure / dizziness: Mild head pressure, tension-type headache, or lightheadedness in a minority — sometimes days 1–5 into a course; often co-blamed on spray technique, dehydration, or Semax co-use. forum
  • Fatigue / mild sedation / flattening: “Too calm,” flat motivation, emotional blunting, or mild drowsiness especially at higher discussed amounts or when stacked with other calming agents — not classic benzo knock-out for most reporters, but a real minority complaint. forum
  • Cognitive dulling / low mood: Minority logs of sedation, cognitive impairment, or depression-like flatness — sometimes when stacked aggressively. anecdote
  • Paradox / first-dose oddities: Rare worse anxiety, restlessness, spacey head, nausea, hot/cold flashes, or brief elevated heart-rate awareness after nasal exposure (sometimes drip-related). anecdote
  • Overstimulation / irritability: Less common than with Semax-class; occasionally reported at higher doses or in sensitive users. forum
  • Vivid dreams: Rare anecdotal reports; not a trial endpoint. anecdote
  • Injection-site issues (if SubQ): Redness, irritation, typical peptide pin discomfort. forum
  • Source / identity risk: Mislabel (plain vs N-acetyl vs dual-capped), underfilled vials, wrong spray concentration, bacterial contamination of multi-use bottles, peptide degradation. forum
  • Autoimmune / immune caution (theoretical): Immune-modulatory (tuftsin-lineage) narrative leads some secondary sources to flag active autoimmune flares or immunosuppressant co-use as caution zones — sparse hard data. forum
  • Pregnancy / breastfeeding: No adequate safety data; secondary clinical writeups list as avoid. forum
  • Dependence narrative gap: Community and Russian summaries emphasize lack of classic benzo withdrawal — that is not proof of zero rebound anxiety after stopping a gray-market course or of long-term self-experimentation safety. forum
  • Desensitization speculation: Some secondary sources warn continuous multi-week+ use might blunt GABA-related response; hard data for capped analogs is essentially none — short courses remain the conservative discussion norm. forum
  • WADA / sport note: Not always named explicitly on prohibited lists; non-approved-substance (S0-style) catch-alls can still apply for tested athletes — jurisdiction-dependent. forum
  • Not risk-free: “Well tolerated in short Russian parent courses” does not make uncontrolled use of any variant risk-free, especially with unknown purity. forum
  • Immunogenicity / compounding flags: FDA Category 2 bulk-substance history for Selank acetate (TP-7) cited immunogenicity, peptide-related impurities, and limited safety information for compounded use; nominator-withdrawal later removed some listings without equaling a safety clearance or approval. Russian registration ≠ US compounding authorization. trial
  • Regulatory gap: Approved prescription nasal product in Russia (and reportedly used in Ukraine) for GAD/neurasthenia-style indications since ~2009; not FDA- or EMA-approved. Research-chem sales elsewhere are not pharmacy therapy. trial
  • Interactions: No robust public interaction tables for SSRIs, SNRIs, benzos, alcohol, stimulants, or other peptides. Parent animal and clinical combination work with benzodiazepines exists — complementary pharmacology, not a self-medication guide. trial
  • Evidence limits: Small, mostly Russian clinical base for parent; English abstracts often thin on exact dose/route details; capped analogs lack independent clinical programs; healthy-enhancement and long-term gray-market use lack Western-grade safety databases. trial

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →